We also don't know the IL28B of the 30 people. Were a mix of cc ct tt ??? We don't know much, but I agree 92% sounds pretty good to me:)
Yes, cirrhotic patients should do 48 weeks even if eRVR. A separate study needs to be done to get more data on this issue, as the number of cirrhotics involved in the for treatment naive patients for Incivek was quite small. Here is the study data.
----------------------------------------------------------------------------------------------
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf
Study 111 (ILLUMINATE)
Study 111 was a randomized, open-label trial conducted in treatment-naïve subjects. The study was designed to compare SVR rates in subjects achieving eRVR who were treated with INCIVEK for 12 weeks in combination with Peg-IFN-alfa-2a/RBV for either 24 weeks (T12/PR24 regimen) or 48 weeks (T12/PR48 regimen).
• Sixty-one (11%) of subjects had cirrhosis at baseline. Among subjects with cirrhosis, 30 (49%) achieved an eRVR: 18 were randomized to T12/PR24 and 12 to T12/PR48. The SVR rates were 67% (12/18) for the T12/PR24 group and 92% (11/12) for the T12/PR48 group.
That's a big difference between 67% and 92%!!!
But again, the group of cirrhotic patients was small (30 patients). Whether these data would be the same in a group of 100s of cirrhotics is unknown.
Cheers! Hector
I found that in the link Wilbb posted. Interesting reading,but as usual the more you read the more confusing it all can get.
always good to let some time go by before making an important decision .